Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Alembic (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide is indicated for hypertension, acting on the renin‑angiotensin system and vascular smooth muscle.

• Essential hypertension: reduces systolic and diastolic blood pressure.
• Hypertension with fluid retention: adds diuretic effect to improve control.
• Hypertension requiring multiple mechanisms: provides combined ARB, calcium‑channel blockade, and diuresis for better efficacy.

• Olmesartan medoxil selectively blocks angiotensin II type‑1 (AT1) receptors, preventing vasoconstriction and aldosterone release. Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. Hydrochlorothiazide promotes sodium and water excretion by inhibiting Na⁺/Cl⁻ reabsorption in the distal convoluted tubule. Together these actions lower peripheral resistance, reduce plasma volume, and achieve synergistic blood‑pressure control.

Common Side Effects

• Dizziness
• Headache
• Peripheral edema
• Flushing
• Cough
• Fatigue

Serious or Rare Side Effects

• Angioedema
• Severe hypotension
• Electrolyte imbalance (e.g., hyper‑ or hypokalemia)
• Acute renal impairment
• Hepatic dysfunction
• Pancreatitis

Before initiating therapy, consider the following precautions:

• Renal function: monitor serum creatinine and potassium levels.
• Electrolytes: check for hypokalemia or hyperkalemia, especially with diuretic use.
• Pregnancy: contraindicated in the second and third trimesters.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Concomitant drugs: avoid NSAIDs that may blunt antihypertensive effect.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Olmesartan Medoxil/Amlodipine/Hydrochlorothiazide may interact with other medicines as follows:

Major Interactions (Avoid)

• Potassium‑sparing diuretics: risk of hyperkalemia.
• ACE inhibitors or aliskiren in diabetic patients: increased risk of renal dysfunction.
• NSAIDs: may reduce antihypertensive efficacy.
• Lithium: increased lithium toxicity.
• Concomitant use with other ARBs: additive renal effects.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole): may raise amlodipine levels.
• CYP3A4 inducers (e.g., rifampicin): may lower amlodipine exposure.
• Antacids containing aluminum or magnesium: may affect absorption.
• Beta‑blockers: additive hypotensive effect.
• Antidiabetic agents: may require dose adjustment due to improved glycemic control.